Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 200 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; pregelatinised maize starch; carnauba wax; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; carnauba wax; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; carnauba wax; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 25 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate; lactose monohydrate; carnauba wax; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.

Iżrael - Ingliż - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 500 iu/vial; von willebrand factor 1300 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

Iżrael - Ingliż - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - glyceryl trinitrate - transdermal patch - 15/24 unknown - 01da02

Ingilterra - Ingliż - myHealthbox

brown & burk uk ltd - irbesartan - film-coated tablets - 150mg - angiotensin-ii antagonists, plain - it is indicated in adults for the treatment of essential hypertension. it is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen

Ingilterra - Ingliż - myHealthbox

brown & burk uk ltd - irbesartan - film-coated tablet - 75mg - angiotensin-ii antagonists, plain - it is indicated in adults for the treatment of essential hypertension. it is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen

Ingilterra - Ingliż - myHealthbox

brown & burk uk ltd - irbesartan - film-coated tablets - 300mg - angiotensin-ii antagonists, plain - it is indicated in adults for the treatment of essential hypertension. it is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen